Gilmore O'Neill - Jun 2, 2022 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
CEO, Director
Signature
/s/ Gilmore O'Neill
Stock symbol
EDIT
Transactions as of
Jun 2, 2022
Transactions value $
$0
Form type
4
Date filed
6/6/2022, 04:44 PM
Previous filing
Jun 6, 2022
Next filing
Jun 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Award $0 +86.7K $0.00 86.7K Jun 2, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EDIT Stock Option (right to buy) Award $0 +950K $0.00 950K Jun 2, 2022 Common Stock 950K $11.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on June 2, 2023 continuing through June 2, 2026.
F2 This option was granted on June 2, 2022 and is scheduled to vest over four years, with 25% of the shares scheduled to vest on June 2, 2023 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through June 2, 2026.